Car-T patient story

in patients with relapsed/refractory multiple myeloma

Aug 9, 2019

Phase I results of the LEGEND-2 trial: LCAR-B38M CAR-T therapy for patients with relapsed or refractory multiple myeloma,LCAR-B38M is a chimeric antigen receptor T-cell (CAR T-cell) therapy that dually binds two distinct B cell maturation antigen (BCMA) epitopes

Know More

Autologous BCMA-CART successfully treats refractory relapsed multiple myeloma with TP53 gene mutation

Aug 02, 2019

Autologous BCMA-CART successfully treats refractory relapsed multiple myeloma with TP53 gene mutation and central nervous system infiltration

Know More

Mr. Chase stayed in the hospital again to receive CAR-T cell r

Aug 02, 2019

Mr. Chase stayed in the hospital again to receive CAR-T cell reinfusion treatment Let the patient get a new life

Know More

Ready to get started?

Gthe earlier you start your treatment, the higher your chances to achieve Complete Remission (CR)

Quick Loan Apply